Daiichi reports Phase III hypertension data

Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) said olmesartan/amlodipine/hydrochlorothiazide triple combination therapy met the primary endpoint of a significantly greater reduction in mean blood pressure from baseline to week 12 vs. corresponding dual combination therapies in the Phase III TRINITY trial to treat hypertension (37.1/21.8 mmHg vs. 27.5-30/15.1-18 mmHg, p<0.0001 for all). The data were from the double-blind portion of the trial, which enrolled 2,492 patients with moderate-to-severe hypertension. Data were presented at the American Society of Hypertension meeting in New York. ...